NorLux will identify and validate novel mechanisms responsible for brain tumour initiation, growth and progression. Using unique patient-derived, pre-clinical animal model systems, combined with large-scale genomics and proteomics technologies, putative therapeutic targets will be identified. NorLux will create effective and tumor-selective therapeutic strategies that complement or substitute established therapies. The overall scientific and coordination objectives are to perform multidisciplinary research efforts of highest international stature within the field of brain tumour biology.